3,6-diazido-2,4-tri-O-acetyl-3,6-dideoxy-α-D-glucopyranosyl trichloroacetimidate | 485809-85-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3,6-diazido-2,4-tri-O-acetyl-3,6-dideoxy-α-D-glucopyranosyl trichloroacetimidate
• CAS: 485809-85-6
• 化学式: C₁₂H₁₄Cl₃N₇O₆
• 分子量: 458.645
• InChiKey: RUEDFMJDDUFTCY-JDDHQFAOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.93
• 重原子数：
  28.0
• 可旋转键数：
  6.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  192.43
• 氢给体数：
  1.0
• 氢受体数：
  9.0

反应信息

• 作为反应物：
  描述：

  3,6-diazido-2,4-tri-O-acetyl-3,6-dideoxy-α-D-glucopyranosyl trichloroacetimidate 在 palladium dihydroxide sodium hydroxide 、 4 A molecular sieve 、 Dowex 1 * 8-200 (Cl^- form) 、 氢气 、 potassium carbonate 、 三甲基膦 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 溶剂黄146 为溶剂， 反应 27.0h， 生成
  参考文献：
  名称：

  Pyranmycins, a Novel Class of Aminoglycosides with Improved Acid Stability:  The SAR of d-Pyranoses on Ring III of Pyranmycin

  摘要：

  The synthesis of a novel class of aminoglycosides, pyranmycins, is reported along with the structure activity relationship (SAR) of their antibacterial activity against Escherichia coli. Two pyranmycins show prominent activity (9 muM). Pyranmycins also manifest superior stability in acidic media. The SAR information will lead to the future designs of pyranmycin against drug resistant bacteria.

  DOI：

  10.1021/ol0269042
• 作为产物：
  描述：

  三氯乙腈 、 Acetic acid (2R,3R,4S,5S,6R)-2,5-diacetoxy-4-azido-6-azidomethyl-tetrahydro-pyran-3-yl ester 在 乙酸肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 N,N-二甲基甲酰胺 、 二氯甲烷 为溶剂， 以63%的产率得到3,6-diazido-2,4-tri-O-acetyl-3,6-dideoxy-α-D-glucopyranosyl trichloroacetimidate
  参考文献：
  名称：

  Pyranmycins, a Novel Class of Aminoglycosides with Improved Acid Stability:  The SAR of d-Pyranoses on Ring III of Pyranmycin

  摘要：

  The synthesis of a novel class of aminoglycosides, pyranmycins, is reported along with the structure activity relationship (SAR) of their antibacterial activity against Escherichia coli. Two pyranmycins show prominent activity (9 muM). Pyranmycins also manifest superior stability in acidic media. The SAR information will lead to the future designs of pyranmycin against drug resistant bacteria.

  DOI：

  10.1021/ol0269042